OVIT OncoVista Innovative Therapies Inc (CE)

An article in this week's BioTuesdays profiled a quiet biotech firm that may begin to make some noise via key acquisitions. Their focus is deep in the middle of the most powerful trend in cancer treatment right now. In fact, OncoVista Innovative Therapies (OTCBB: OVIT) has been developing specialized drugs that target leukemia, colon, breast and prostate cancers for some time -- all the while knowing that cancer patients do not respond uniformly to a given drug regimen.

As oncologists tell us, one highly efficacious treatment for a cancer patient is often ineffective for another -- even if these patients present an identical diagnosis.

The solution offered by OVIT includes detecting cancer cells circulating in the bloodstream, which express certain biomarkers. By doing this, doctors can treat patients with a targeted drugs.

"We use diagnostic technologies to determine which patients are most likely to benefit from a drug candidate -- and which patients won't," says Alexander Weis, Founder, CEO OncoVista Innovative Therapies. "Equally important, our business strategy is to acquire other drug candidates as well as acquiring diagnostic tools that will enable us to develop faster, more effective, less toxic and cheaper cancer treatment regimens."

OncoVista certainly appears to have the experience and the funds to realize its ambition.

A special report about OncoVista and their drug compounds is now available at: http://biomedreports.com/2011051167067/oncovista-positioning-itself-to-go-to-the-next-level.html

In addition, investors interested in accessing BioMedReports' new complete database of clinical trials and upcoming FDA and world-wide regulatory decisions can go to: http://biomedreports.com/access-our-exclusive-fda-and-clinical-trials-calendars.html

News developments and live healthcare sector updates are available constantly via twitter at: http://twitter.com/BioMedReports

About BioMedReports.Com

BioMedReports is a news portal covering the biomedical news and financial sector. BioMedReports is not paid or compensated to report the news and developments of publicly traded companies in the healthcare sector of the markets.

Full disclosures and information about the stocks are available at BioMedReports.Com

Add to Digg Bookmark with del.icio.us Add to Newsvine

Media Contacts Only: Mary Davila Assistant Editor BioMedReports.Com e-mail: Email Contact Tel: +1 323 472 4480 Fax: +1 888 210 3556